187 related articles for article (PubMed ID: 31730793)
1. N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Neale JH; Yamamoto T
Prog Neurobiol; 2020 Jan; 184():101722. PubMed ID: 31730793
[TBL] [Abstract][Full Text] [Related]
2. NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.
Olszewski RT; Janczura KJ; Bzdega T; Der EK; Venzor F; O'Rourke B; Hark TJ; Craddock KE; Balasubramanian S; Moussa C; Neale JH
Neurochem Res; 2017 Sep; 42(9):2646-2657. PubMed ID: 28285415
[TBL] [Abstract][Full Text] [Related]
3. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
Bařinka C; Rojas C; Slusher B; Pomper M
Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
[TBL] [Abstract][Full Text] [Related]
4. Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG).
Hicks C; Gregg RA; Nayak SU; Cannella LA; Schena GJ; Tallarida CS; Reitz AB; Smith GR; Rawls SM
Psychopharmacology (Berl); 2017 Jun; 234(11):1671-1681. PubMed ID: 28251297
[TBL] [Abstract][Full Text] [Related]
5. A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA.
Nonaka T; Yamada T; Ishimura T; Zuo D; Moffett JR; Neale JH; Yamamoto T
Mol Pain; 2017 Jan; 13():1744806917697008. PubMed ID: 28326936
[TBL] [Abstract][Full Text] [Related]
6. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate.
Bacich DJ; Ramadan E; O'Keefe DS; Bukhari N; Wegorzewska I; Ojeifo O; Olszewski R; Wrenn CC; Bzdega T; Wroblewska B; Heston WD; Neale JH
J Neurochem; 2002 Oct; 83(1):20-9. PubMed ID: 12358725
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
8. Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.
Vornov JJ; Hollinger KR; Jackson PF; Wozniak KM; Farah MH; Majer P; Rais R; Slusher BS
Adv Pharmacol; 2016; 76():215-55. PubMed ID: 27288079
[TBL] [Abstract][Full Text] [Related]
9. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.
Neale JH; Olszewski RT; Zuo D; Janczura KJ; Profaci CP; Lavin KM; Madore JC; Bzdega T
J Neurochem; 2011 Aug; 118(4):490-8. PubMed ID: 21644997
[TBL] [Abstract][Full Text] [Related]
10. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
11. A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition.
Neale JH; Olszewski R
Neurobiol Learn Mem; 2019 Feb; 158():9-13. PubMed ID: 30630041
[TBL] [Abstract][Full Text] [Related]
12. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia.
Neale JH; Olszewski RT; Gehl LM; Wroblewska B; Bzdega T
Trends Pharmacol Sci; 2005 Sep; 26(9):477-84. PubMed ID: 16055199
[TBL] [Abstract][Full Text] [Related]
13.
Morland C; Nordengen K
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163193
[No Abstract] [Full Text] [Related]
14. NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Olszewski RT; Janczura KJ; Ball SR; Madore JC; Lavin KM; Lee JC; Lee MJ; Der EK; Hark TJ; Farago PR; Profaci CP; Bzdega T; Neale JH
Transl Psychiatry; 2012 Jul; 2(7):e145. PubMed ID: 22850437
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
16. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors.
Urazaev AK; Grossfeld RM; Lieberman EM
J Neurochem; 2005 May; 93(3):605-10. PubMed ID: 15836619
[TBL] [Abstract][Full Text] [Related]
17. Deletion of glutamate carboxypeptidase II (GCPII), but not GCPIII, provided long-term benefits in mice with traumatic brain injury.
Ji T; Pang Y; Cheng M; Wang R; Chen X; Zhang C; Liu M; Zhang J; Zhong C
CNS Neurosci Ther; 2023 Dec; 29(12):3786-3801. PubMed ID: 37349952
[TBL] [Abstract][Full Text] [Related]
18. Blockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders.
Zhong C; Luo Q; Jiang J
Int J Neurosci; 2014 Dec; 124(12):867-73. PubMed ID: 24494725
[TBL] [Abstract][Full Text] [Related]
19. Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain.
Yamamoto T; Kozikowski A; Zhou J; Neale JH
Mol Pain; 2008 Aug; 4():31. PubMed ID: 18673570
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
